b.2 January 1963 d.2 October 2005
MB BCh Witwatersrand(1986) MRCP(1990) PhD Lond(1995) FRCP(2004)
David Vigushin was an outstanding clinical scientist based at Imperial College, London. He studied medicine at the University of Witwatersrand Medical School, Johannesburg, South Africa, having won the University Council Scholarship Award. He had previously matriculated from Eden College with a distinction in six subjects.
He went to the UK in 1988, and in 1990 became a research fellow in immunological medicine for M B Pepys. In 1993, he became a clinical lecturer in medical oncology and worked through the medical oncology rotation. In 1995 he was awarded a PhD for his work on plasma pentraxins and amyloidosis. He was accredited by the Joint Committee on Higher Medical Training in Medical Oncology in 1996 and became senior lecturer in cancer medicine at Imperial College, and honorary consultant physician in cancer medicine at the Hammersmith Hospitals Trust in 2000.
David obtained the Young Investigator Award in 1997 from the American Association for Cancer Research and his work is published in many prestigious journals, including the Proceedings of the National Academy of Sciences and Nature. David's publications and research work focused on the development of novel treatments for breast cancer and, in particular, inhibitors of histone deacetylase, on which he was asked to lecture in several countries worldwide.
David had a team based at the Hammersmith Hospital and his clinical duties were at Charing Cross in the medical breast unit. He was an outstandingly kind and considerate doctor, who, despite being involved in the treatment of seriously ill patients on a daily basis, never lost his sensitivity and empathy. He was never proud or overbearing. His outstanding modesty and self-effacement were noticeable features of his personality, and this was greatly appreciated by the staff, for whom he became a considerate mentor. No chore ever seemed too much for him, no task too difficult to undertake.
R C Coombes
(Volume XII, page web)
<< Back to List